Replies to post #251541 on Elite Pharmaceuticals Inc (ELTP)

[jour_trader]

If the results are positive in May, the trajectory the stock will be on a rising trajectory and a higher base will form.

[jour_trader]

Also, a summary of results is fine for me. If these results aren't good then it may be time for new management as this process for a resubmission of SequestOx has taken far far too long. I'll wait until we hear more before making any judgment. I am expecting a positive outcome early June. I have learned over the years that Nasrat does not under promise & over deliver. Despite Nasrat saying results are expected mid-May, he never accounts for any hiccups in the process and does not build in flexibility. If we hear before the end of May I will be thrilled, but not holding my breath.

[Couch]

Everyone knows

Indeed, everyone knows that positive BE data is coming!!!

TICK TOCK TICK TOCK

Elite Pharmaceuticals, Inc. Initiates Pivotal Bioequivalence Fed Study For Reformulated SequestOx™

NORTHVALE, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP), announced today that it has initiated pharmacokinetic testing of its reformulated SequestOx™. The reformulated product is expected to have a shorter Tmax under fed conditions. Elite is conducting a bioequivalence study which is a pivotal, open-label, randomized, single-dose, three-way, crossover study to evaluate the relative comparative bioavailability and bioequivalence of the modified formulation of SequestOx™ to the original formulation of SequestOx™ and to a comparator product under fed conditions. The study has enrolled forty-five healthy volunteers and the first subjects have been dosed.

SequestOx™ is Elite's investigational immediate-release oxycodone with sequestered naltrexone abuse-deterrent opioid product for the management of moderate to severe acute pain where the use of an opioid analgesic is appropriate.

"We are pleased to have this bioequivalence study underway for SequestOx™," commented Nasrat Hakim, President and CEO of Elite. "We are expecting results for this study by the middle of May and re-submitting the NDA prior to the end of the year."